Hepatitis Monthly

Published by: Kowsar

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B

Fatemeh Bakhshizadeh 1 , Soheila Hekmat 1 , * , Maryam Keshvari 2 , Seyed Moayed Alavian 3 , Ehsan Mostafavi 4 , Hossein Keivani 5 , Amin Doosti-Irani 6 , Fatemeh Motevalli 1 and Bita Behnava 3
Authors Information
1 Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, IR Iran
2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
3 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
4 Epidemiology Department, Pasteur Institute of Iran, Tehran, IR Iran
5 Virology Department, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
6 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e25749
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: December 1, 2014
  • Revised: January 28, 2015
  • Accepted: April 14, 2015
  • DOI: 10.5812/hepatmon.15(5)2015.25749

To Cite: Bakhshizadeh F, Hekmat S, Keshvari M, Alavian S M, Mostafavi E, et al. Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B, Hepat Mon. 2015 ;15(5):e25749. doi: 10.5812/hepatmon.15(5)2015.25749.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, de Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother. 1994; 38(9): 2180-2[PubMed]
  • 2. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23): 2442-55[DOI][PubMed]
  • 3. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140(1): 132-43[DOI][PubMed]
  • 4. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381(9865): 468-75[DOI][PubMed]
  • 5. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology. 2012; 55(1): 307-15[DOI][PubMed]
  • 6. Huntzinger A. AASLD Updates Chronic Hepatitis B Recommendations. Am Fam Physician. 2009; 79(4): 338-43
  • 7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 8. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
  • 9. Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010; 85(3): 512-9[DOI][PubMed]
  • 10. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013; 58(2): 505-13[DOI][PubMed]
  • 11. Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol. 2014; 20(23): 7169-80[DOI][PubMed]
  • 12. Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013; 57(4): 1790-6[DOI][PubMed]
  • 13. Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013; 28(5): 855-60[DOI][PubMed]
  • 14. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49(4): 634-51[DOI][PubMed]
  • 15. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009; 51(1): 11-20[DOI][PubMed]
  • 16. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126(7): 1750-8[PubMed]
  • 17. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007; 5(12): 1462-8[DOI][PubMed]
  • 18. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011; 106(10): 1766-73[DOI][PubMed]
  • 19. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011; 53(5): 1486-93[DOI][PubMed]
  • 20. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis. 2011; 204(3): 415-8[DOI][PubMed]
  • 21. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52(5): 1611-20[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments